S&P 500

5.222,68

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
SQZ Biotechnologies Company (SQZ)
SQZ Biotechnologies Company (SQZ) Notícias

SQZ

SQZ Biotechnologies (SQZ)

SQZ Biotechnologies Company

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:SQZ

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
06/05/2024	07:25	GlobeNewswire Inc.	Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider	NYSE:SQZ	SQZ Biotechnologies Company
23/01/2024	18:31	Edgar (US Regulatory)	Form DEFM14A - Definitive proxy statement relating to merger or acquisition	NYSE:SQZ	SQZ Biotechnologies Company
22/12/2023	19:18	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:SQZ	SQZ Biotechnologies Company
08/11/2023	18:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:SQZ	SQZ Biotechnologies Company
15/06/2023	17:47	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:SQZ	SQZ Biotechnologies Company
15/06/2023	17:38	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:SQZ	SQZ Biotechnologies Company
15/06/2023	17:30	Business Wire	SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split	NYSE:SQZ	SQZ Biotechnologies Company
10/05/2023	17:45	Business Wire	SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates	NYSE:SQZ	SQZ Biotechnologies Company
10/05/2023	17:35	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:SQZ	SQZ Biotechnologies Company
05/05/2023	17:32	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NYSE:SQZ	SQZ Biotechnologies Company
26/04/2023	17:32	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NYSE:SQZ	SQZ Biotechnologies Company
26/04/2023	17:31	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NYSE:SQZ	SQZ Biotechnologies Company
10/04/2023	17:32	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NYSE:SQZ	SQZ Biotechnologies Company
22/03/2023	17:50	Business Wire	SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial	NYSE:SQZ	SQZ Biotechnologies Company
22/03/2023	17:45	Business Wire	SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates	NYSE:SQZ	SQZ Biotechnologies Company
14/02/2023	16:25	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NYSE:SQZ	SQZ Biotechnologies Company
18/01/2023	18:30	Business Wire	SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange	NYSE:SQZ	SQZ Biotechnologies Company
06/12/2022	13:55	TipRanks	SQZ Biotechnologies (SQZ) Gets a Hold from H.C. Wainwright	NYSE:SQZ	SQZ Biotechnologies Company
06/12/2022	10:55	TipRanks	SQZ Biotechnologies (SQZ) Receives a Buy from Brookline Capital Markets	NYSE:SQZ	SQZ Biotechnologies Company
06/12/2022	08:45	Business Wire	SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress	NYSE:SQZ	SQZ Biotechnologies Company
02/12/2022	08:15	TipRanks	SQZ Biotechnologies (SQZ) was downgraded to a Hold Rating at H.C. Wainwright	NYSE:SQZ	SQZ Biotechnologies Company
01/12/2022	09:55	TipRanks	Chardan Capital Sticks to Their Buy Rating for SQZ Biotechnologies (SQZ)	NYSE:SQZ	SQZ Biotechnologies Company
30/11/2022	18:30	Business Wire	SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer	NYSE:SQZ	SQZ Biotechnologies Company
10/11/2022	11:00	Business Wire	SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting	NYSE:SQZ	SQZ Biotechnologies Company
10/11/2022	08:17	TipRanks	SQZ Biotechnologies (SQZ) Receives a Buy from H.C. Wainwright	NYSE:SQZ	SQZ Biotechnologies Company
09/11/2022	21:55	TipRanks	Brookline Capital Markets Reaffirms Their Buy Rating on SQZ Biotechnologies (SQZ)	NYSE:SQZ	SQZ Biotechnologies Company
09/11/2022	18:30	Business Wire	SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates	NYSE:SQZ	SQZ Biotechnologies Company
03/10/2022	07:45	Business Wire	SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy	NYSE:SQZ	SQZ Biotechnologies Company
12/09/2022	10:15	TipRanks	Brookline Capital Markets Keeps Their Buy Rating on SQZ Biotechnologies (SQZ)	NYSE:SQZ	SQZ Biotechnologies Company
12/09/2022	07:00	Business Wire	SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies	NYSE:SQZ	SQZ Biotechnologies Company